Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 265

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Extrapyramidal side-effects of antipsychotics in a randomised trial

Open access
Miller, Del D., Caroff, Stanley N., Davis, Sonia M., Rosenheck, Robert A., McEvoy, Joseph P., Saltz, Bruce L., Riggio, Silvana, Chakos, Miranda H., Swartz, Marvin S., Keefe, Richard S.E., Stroup, T. Scott, Lieberman, Jeffrey A., for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators·2008·British Journal of Psychiatry

Abstract

Background: There are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs. Aims: To compare the incidence of treatment-emergent EPS between second-generation antipsychotics and perphenazine in people with schizophrenia. Method: Incidence analyses integrated data from standardised rating scales and documented use of concomitant medication or treatment discontinuation for EPS events. Mixed model analyses of change in rating scales from baseline were also conducted. Results: There were no significant differences in incidence or change in rating scales for parkinsonism, dystonia, akathisia or tardive dyskinesia when comparing second-generation antipsychotics with perphenazine or comparing between second-generation antipsychotics. Secondary analyses revealed greater rates of concomitant antiparkinsonism medication among individuals on risperidone and lower rates among individuals on quetiapine, and lower rates of discontinuation because of parkinsonism among people on quetiapine and ziprasidone. There was a trend for a greater likelihood of concomitant medication for akathisia among individuals on risperidone and perphenazine. Conclusions: The incidence of treatment-emergent EPS and change in EPS ratings indicated that there are no significant differences between second-generation antipsychotics and perphenazine or between second-generation antipsychotics in people with schizophrenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1192/bjp.bp.108.050088

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 265

Metadata

Authors
Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., Riggio, S., Chakos, M. H., Swartz, M. S., Keefe, R. S. E., Stroup, T. S., Lieberman, J. A., & for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Venue
British Journal of Psychiatry
Published
2008-10
Volume
193
Issue
4
Pages
279-288
ISSN
  • 0007-1250 (ISSN-L)
  • 1472-1465
OpenAlex
W2002442062
Cited by
265
References
59
FWCI
14.21
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extrapyramidal side-effects of antipsychotics in a randomised trial. https://app.cochat.ai/papers/10.1192/bjp.bp.108.050088
The paper
Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., Riggio, S., Chakos, M. H., Swartz, M. S., Keefe, R. S. E., Stroup, T. S., Lieberman, J. A., & for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. (2008). Extrapyramidal side-effects of antipsychotics in a randomised trial. British Journal of Psychiatry. https://doi.org/10.1192/bjp.bp.108.050088

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.